deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00899054

Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer (SPARK)

An Open Label, Multicenter Phase I/II Study Of Selective Cyclin Dependent Kinase Inhibitor P276-00 In Combination With Radiation In Subjects With Recurrent And/Or Locally Advanced Squamous Cell Carcinoma Of Head And Neck

Sponsor: Piramal Enterprises Limited

Conditions Squamous Cell Carcinoma of Head and Neck
Interventions External beam radiotherapy (EBRT) P276-00
Updated 5 times since 2017 Last updated: Nov 21, 2012 Started: Aug 31, 2009 Primary completion: Jan 31, 2011 Completion: Nov 30, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00899054, this PHASE1/PHASE2 trial focuses on Squamous Cell Carcinoma of Head and Neck and remains completed. Sponsored by Piramal Enterprises Limited, it has been updated 5 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Piramal Enterprises Limited
Data source: Piramal Enterprises Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations